Alkem launches NeuCeno for epilepsy treatment
Alkem launches NeuCeno (cenobamate) for partial-onset seizures. The drug is approved for adult patients and marks a strategic expansion in Alkem’s neurology portfolio. Launch may drive future revenue with first-to-market advantage in India. NeuCeno is a globally recognized anti-epileptic drug.
📊 STOCKS: $ALKEM | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Launch
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.